Abstract
Introduction
Immunotherapy by checkpoint inhibitors, i.e., anti-programmed death-1(PD-1) or anti-programmed death-ligand 1 (PD-L1) antibodies, has gained more attention managing solid tumors. Pembrolizumab (an anti-PD-1 antibody) in metastatic colorectal cancer (CRC) was approved in 2017 by the US FDA.
Reason for the report
Pembrolizumab is not effective in microsatellite stable, mismatch-repair-proficient (MSS-pMMR) molecular phenotype, which comprises most CRC patients. In this report, we present the first case of metastatic CRC with a dramatic and durable response to pembrolizumab despite being of MSS-pMMR phenotype.
Case summary
A 34-year-old woman, presented seven years ago with T3N2bM0 colon cancer and an appendix carcinoid tumor. The last relapse with bilateral pulmonary metastases was refractory to all treatments. Although it seemed unresponsive to immunotherapy because of MSS molecular phenotype, due to the high expression level of PD-L1 (85%), we started treatment with pembrolizumab 200 mg every three weeks and continued for the overall 19 courses. Surprisingly, a rapid and complete response was observed that last until now, i.e., 17 months after discontinuation of pembrolizumab.
Outcome
Despite non-promising results in the current clinical trials, MSS-pMMR colorectal cancer patients' deprivation from immunotherapy seems not to be reasonable. There are ongoing clinical trials on checkpoint inhibitors either alone or in combination with other drugs. However, immunostaining for PD-L1 should be considered as a possible response predictor.
Graphical abstract
Immunotherapy either by cell-based approaches or by checkpoint inhibitors may revolutionize cancer treatment
Pembrolizumab has been approved by the FDA in 2017 for colorectal cancer.
However, MSS-pMMR molecular phenotype which comprises the majority of CRC patients, has not shown a good response to checkpoint inhibitors.
We present a MSS-pMMR case with complete and durable response to pembrolizumab
We suggest immunostaining for PD-L1 as a possible response predictor to checkpoint inhibitors
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gong J, Wang C, Lee PP, et al. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation. J Natl Compr Canc Netw. 2017;15(2):142–7. https://doi.org/10.6004/jnccn.2017.0016.
Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–75. https://doi.org/10.1038/s41575-019-0126-x.
Le DT, Uram JN, Wang H, et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. Journal of Clinical Oncology. 2016;34(15_suppl):103–103. https://doi.org/10.1200/JCO.2016.34.15_suppl.103.
Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91.
O’Neil BH, Wallmark JM, Lorente D, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS ONE. 2017;12(12): e0189848. https://doi.org/10.1371/journal.pone.0189848.
Jacobs J, Smits E, Lardon F, et al. Immune checkpoint modulation in colorectal cancer: what’s new and what to expect. J Immunol Res. 2015;2015: 158038. https://doi.org/10.1155/2015/158038.
Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74. https://doi.org/10.1126/science.aaa4971.
Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer. Front Oncol. 2019;9:396. https://doi.org/10.3389/fonc.2019.00396.
Kreidieh M, Mukherji D, Temraz S, et al. Expanding the scope of immunotherapy in colorectal cancer: current clinical approaches and future directions. Biomed Res Int. 2020;2020:9037217. https://doi.org/10.1155/2020/9037217[publishedOnlineFirst:2020/02/25].
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.
Lee JJ, Sun W, Bahary N, et al. Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer: Journal of Clinical Oncology. 2017;35(15_suppl):3054–3054. https://doi.org/10.1200/JCO.2017.35.15_suppl.3054.
Bendell JC, Kim TW, Goh BC, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). Journal of Clinical Oncology 34, no. 15_suppl (May 20, 2016) 3502–3502. https://doi.org/10.1200/JCO.2016.34.15_suppl.3502.
Sorscher S, Resnick J, Goodman M. First case report of a dramatic radiographic response to a checkpoint inhibitor in a patient with proficient mismatch repair gene expressing metastatic colorectal cancer. JCO Precis Oncol. 2017;1:1–4. https://doi.org/10.1200/PO.16.00005.
Cui G. The mechanisms leading to distinct responses to PD-1/PD-L1 blockades in colorectal cancers with different MSI statuses. Front Oncol. 2021;11: 573547. https://doi.org/10.3389/fonc.2021.573547[publishedOnlineFirst:2021/03/26].
Le Flahec G, Badic B, Guibourg B, et al. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. Hum Pathol. 2018;72:135–43. https://doi.org/10.1016/j.humpath.2017.09.019[publishedOnlineFirst:2017/12/07].
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gomar, M., Najafi, M., Aghili, M. et al. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer. DARU J Pharm Sci 29, 501–506 (2021). https://doi.org/10.1007/s40199-021-00404-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40199-021-00404-w